MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - BIOCON
ASTRAZENECA PHARMA vs BIOCON - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
BIOCON 
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
Current Valuations
| ASTRAZENECA PHARMA | BIOCON | ASTRAZENECA PHARMA/ BIOCON |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 96.6 | 22.2 | 434.4% | View Chart |
| P/BV | x | 27.2 | 2.9 | 923.7% | View Chart |
| Dividend Yield | % | 0.0 | 0.4 | - |
Financials
 ASTRAZENECA PHARMA  BIOCON |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
BIOCON Mar-18 |
ASTRAZENECA PHARMA/ BIOCON |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 1,188 | 107.6% | |
| Low | Rs | 883 | 305 | 289.4% | |
| Sales per share (Unadj.) | Rs | 228.4 | 68.7 | 332.3% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 7.6 | 137.2% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 14.0 | 116.4% | |
| Dividends per share (Unadj.) | Rs | 0 | 1.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.1 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 86.3 | 114.4% | |
| Shares outstanding (eoy) | m | 25.00 | 600.00 | 4.2% | |
| Bonus/Rights/Conversions | - | IS | - | ||
| Price / Sales ratio | x | 4.7 | 10.9 | 43.5% | |
| Avg P/E ratio | x | 104.2 | 98.9 | 105.4% | |
| P/CF ratio (eoy) | x | 66.4 | 53.4 | 124.3% | |
| Price / Book Value ratio | x | 10.9 | 8.6 | 126.5% | |
| Dividend payout | % | 0 | 13.2 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 447,900 | 6.0% | |
| No. of employees | `000 | 1.4 | 6.1 | 22.1% | |
| Total wages/salary | Rs m | 1,535 | 9,311 | 16.5% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 6,705.8 | 62.8% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 1,514.2 | 74.8% | |
| Avg. net profit/employee | Rs Th | 191.1 | 736.9 | 25.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 41,234 | 13.8% | |
| Other income | Rs m | 123 | 2,062 | 5.9% | |
| Total revenues | Rs m | 5,833 | 43,296 | 13.5% | |
| Gross profit | Rs m | 463 | 8,291 | 5.6% | |
| Depreciation | Rs m | 147 | 3,851 | 3.8% | |
| Interest | Rs m | 0 | 615 | 0.0% | |
| Profit before tax | Rs m | 438 | 5,887 | 7.4% | |
| Minority Interest | Rs m | 0 | 213 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 1,569 | 11.4% | |
| Profit after tax | Rs m | 259 | 4,531 | 5.7% | |
| Gross profit margin | % | 8.1 | 20.1 | 40.3% | |
| Effective tax rate | % | 40.8 | 26.7 | 153.3% | |
| Net profit margin | % | 4.5 | 11.0 | 41.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 41,486 | 7.7% | |
| Current liabilities | Rs m | 2,070 | 21,413 | 9.7% | |
| Net working cap to sales | % | 20.0 | 48.7 | 41.0% | |
| Current ratio | x | 1.6 | 1.9 | 80.0% | |
| Inventory Days | Days | 72 | 64 | 113.1% | |
| Debtors Days | Days | 35 | 94 | 37.1% | |
| Net fixed assets | Rs m | 790 | 50,661 | 1.6% | |
| Share capital | Rs m | 50 | 3,000 | 1.7% | |
| "Free" reserves | Rs m | 2,419 | 48,808 | 5.0% | |
| Net worth | Rs m | 2,469 | 51,808 | 4.8% | |
| Long term debt | Rs m | 0 | 17,898 | 0.0% | |
| Total assets | Rs m | 4,605 | 99,897 | 4.6% | |
| Interest coverage | x | NM | 10.6 | - | |
| Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.4 | 300.4% | |
| Return on assets | % | 5.6 | 5.2 | 109.2% | |
| Return on equity | % | 10.5 | 8.7 | 120.0% | |
| Return on capital | % | 17.7 | 9.6 | 184.1% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 12,058 | 2.5% | |
| Fx outflow | Rs m | 2,015 | 7,348 | 27.4% | |
| Net fx | Rs m | -1,715 | 4,710 | -36.4% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 6,621 | 1.3% | |
| From Investments | Rs m | -94 | -6,840 | 1.4% | |
| From Financial Activity | Rs m | NA | -2,397 | 0.0% | |
| Net Cashflow | Rs m | -6 | -2,612 | 0.2% | |
Share Holding
| Indian Promoters | % | 0.0 | 40.4 | - | |
| Foreign collaborators | % | 75.0 | 20.6 | 364.1% | |
| Indian inst/Mut Fund | % | 0.3 | 8.4 | 3.6% | |
| FIIs | % | 15.7 | 10.7 | 146.7% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 19.9 | 45.7% | |
| Shareholders | 12,856 | 109,995 | 11.7% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: CADILA HEALTHCARE TTK HEALTHCARE SHASUN PHARMA DISHMAN PHARMA J.B.CHEMICALS
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 76 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)
India share markets witnessed selling pressure during closing hours and ended their volatile day marginally lower.
Related Views on News
BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)
Nov 1, 2019 | Updated on Nov 1, 2019For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)
Jul 29, 2019 | Updated on Jul 29, 2019For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)
Apr 26, 2019 | Updated on Apr 26, 2019For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsMost Popular
The Smartest Stock to Buy for 2020(Profit Hunter)
Nov 14, 2019Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...
A Trade that Could Generate Profits for Decades
Nov 14, 2019India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
The One Trade I'm Most Bullish on Now
Nov 12, 2019A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!
How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)
Nov 14, 2019Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.
MoreASTRAZENECA PHARMA SHARE PRICE
Nov 21, 2019 03:37 PM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - AUROBINDO PHARMA COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.